Iterum Therapeutics (ITRM) Competitors

Iterum Therapeutics (NASDAQ:ITRM) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.

Does the MarketBeat Community prefer ITRM or ACRV?

Iterum Therapeutics received 106 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote.

Company	Underperform	Outperform
Iterum Therapeutics	Outperform Votes 141 62.95%	Underperform Votes 83 37.05%
Acrivon Therapeutics	Outperform Votes 35 97.22%	Underperform Votes 1 2.78%

Which has more volatility & risk, ITRM or ACRV?

Iterum Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Does the media prefer ITRM or ACRV?

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Iterum Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 2 mentions for Iterum Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.99 beat Iterum Therapeutics' score of 0.66 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iterum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, ITRM or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	N/A	N/A	-$24.77M	-$1.31	-1.14
Acrivon Therapeutics	N/A	N/A	-$60.39M	-$2.70	-2.05

Do analysts rate ITRM or ACRV?

Iterum Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 234.45%. Acrivon Therapeutics has a consensus price target of $23.67, suggesting a potential upside of 327.20%. Given Acrivon Therapeutics' higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Acrivon Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ITRM or ACRV more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-90.85%
Acrivon Therapeutics	N/A	-47.95%	-43.73%

Do insiders & institutionals believe in ITRM or ACRV?

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Iterum Therapeutics and Acrivon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.